Rituximab for immune-related side effects from melanoma immunotherapy
Treatments studied
Part of Cancer, Skin clinical trials.
This phase 1 trial tests whether rituximab (a drug that targets certain immune cells) can help reduce side effects caused by immunotherapy. The goal is to find a safe dose and see if it improves symptoms without harming your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to read and understand Danish.
- You must have a confirmed diagnosis of melanoma (a type of skin cancer).
- You must have received immunotherapy (drugs like PD-1/PD-L1/CTLA-4 inhibitors) for melanoma within the last 3 months.
- You must be experiencing immune-related side effects (like skin, gut, or lung inflammation) that are moderate to severe (grade 2-4).
- You must not have an active infection, low blood cell counts, serious heart problems, or be taking certain other medications (except steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether rituximab, a medication that calms the immune system, can help people with certain nerve or brain conditions linked to a specific antibody. It aims to reduce symptoms or prevent the disease from getting worse.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
This study looks at how people with advanced melanoma (a serious skin cancer) feel during treatment with immunotherapy. It aims to better understand the symptoms they experience, so doctors can help manage them.
Hear when a new Immune-Related Adverse Events trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.